AI 'Zhiliao Doctor' aims to ease anxiety in breast cancer patients on CDK4/6 inhibitors

NCT ID NCT07409298

ENROLLING_BY_INVITATION Symptom relief Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether an AI-based management platform, called 'Zhiliao Doctor,' can reduce anxiety and depression in 300 breast cancer patients taking CDK4/6 inhibitors at home. Participants are randomly assigned to standard care, the AI platform, or personalized follow-up calls. The study measures changes in mood, quality of life, and medication adherence over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zhiliao Doctor AI management platform (device) and tailored active follow-up (behavioral intervention)
What this could lead to: If successful, this could show that AI-based support helps breast cancer patients feel less anxious and depressed while managing their treatment at home.
What could go wrong: This is a relatively small, early-stage trial focused on psychological outcomes, not survival. The AI platform may not significantly improve mental health, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer mixed anxiety and depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER CDK4/6 INHIBITORS DEPRESSION ANXIETY DISORDER

Contacts and locations

Locations

Tianjin Medical University Cancer Institute & Hospital

Tianjin, 300000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.